FDA approves Astellas' once-daily tacrolimus

FDA approved an NDA from Astellas Pharma Inc. (Tokyo:4503) for Astagraf XL tacrolimus extended-release capsules to prevent organ rejection in adult kidney transplant recipients. Astellas already marke...